PASG
Good news, then a very biotech kind of “but”
Passage Bio says its PBFT02 gene therapy is showing encouraging interim biomarker improvements in its Phase 1/2 upliFT-D study for frontotemporal dementia with GRN mutations. In plain English: the science is moving in the right direction, which is the part investors like to see when they’re betting on a high-risk, high-reward pipeline asset.
The FDA just moved the goalposts
Here’s the catch. After a Type C meeting, the FDA told Passage Bio that PBFT02 will need a randomized controlled registrational trial for approval in FTD-GRN. Translation: the agency is not buying the company’s single-arm plan, which likely means more time, more patients, and more money before any shot at approval.
And now the company is shopping the whole playbook
As if that weren’t enough moving parts, Passage Bio also launched a comprehensive strategic review. That means management is weighing options like a merger, acquisition, asset sale, licensing deal, or other corporate makeover to maximize shareholder value. The company hired Wedbush PacGrow to help with the process, which is basically Wall Street’s version of bringing in a matchmaker.
Big picture: the data may have been encouraging, but the FDA’s demand for a tougher trial adds a real financing and timeline burden. That makes the strategic review feel less like a side quest and more like the main event.